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ABSTRACT
Between July 1997 and August 2004, 146 consecutive patients with hematologic malignancies received a T
cell–depleted peripheral blood stem cell transplant from an HLA-identical sibling by using total body irradi-
ation (TBI) and cyclophosphamide conditioning regimens. Eighty-five patients received 13.6 Gy of TBI with
no lung shielding, and 61 received lung shielding (total lung dose, 6-12 Gy). Ninety-four patients (65.5%) had
standard-risk disease; the remainder had more advanced disease or unfavorable diagnoses. Of the 21 trans-
plant-related deaths, 14 were from pulmonary causes (10 idiopathic pulmonary syndromes and 4 from
infection) that occurred at a median of 90 days (range, 23-238 days) after transplantation. Independent risk
factors for pulmonary transplant-related mortality (PTRM) were pretransplantation diffusion capacity for
carbon monoxide (relative risk, 5.7 for diffusion capacity for carbon monoxide <85%), smoking (relative risk,
5.0), and CD34 cell dose (relative risk, 9.4 for a CD34 dose of <5  106 cells per kilogram). Patients receiving
lung shielding had significantly lower PTRM (3.3% versus 14.1%; P  .02) and better overall survival (70% 
6% versus 52%  5%; P  .04), but lung shielding was not a significant independent factor for determining
PTRM. These results suggest that pulmonary mortality after TBI-based preparative regimens is predictable
and that higher CD34 cell doses can reduce the risk.
© 2005 American Society for Blood and Marrow Transplantation
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PNTRODUCTION
Although allogeneic stem cell transplantation (SCT)
s the only curative treatment for some hematologic
alignancies, success is limited by transplant-related
ortality (TRM). Although reduced-intensity transplant
onditioning regimens result in improved regimen-re-
ated toxicity, they are less effective at disease control [1].
ntensive conditioning regimens using total body irradi-
tion (TBI) remain the most effective way to prevent
elapse of disease after transplantation. However, ap-
roximately 20% of patients given such myeloablative
onditioning regimens die of transplant-related causes
1,2]. Although multiple factors such as infection, graft-
ersus-host disease (GVHD) and its treatment, and reg-
men-related toxicity contribute to TRM, the most fre- c
B&MTuent proximal causes of death are ventilatory failure,
epatic failure, and major injury to the central nervous
ystem. Because the prevention and treatment of GVHD
nd infection have improved, regimen-related toxicity
ccounts for an increasing proportion of TRM after
CT.
Because death related to pulmonary failure has been
he major contributor to TRM in transplant recipients
iven TBI conditioning regimens, we investigated ways
o predict pulmonary TRM (PTRM) by studying pre-
ransplantation patient characteristics and measuring
ulmonary function. In an attempt to reduce PTRM, we
lso introduced lung shielding to limit the TBI dose to
he lungs. Here we describe factors that determine
TRM and describe a favorable transplantation out-
ome in recipients of TBI with lung shielding.
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2ATERIALS AND METHODS
tudy Group
Between July 1997 and August 2004, 146 consecu-
ive patients with hematologic malignancies received a T
ell–depleted peripheral blood SCT (PBSCT) from an
LA-identical sibling in 5 successive National Heart,
ung, and Blood Institute (NHLBI) institutional review
oard–approved protocols (97-H-0099, 99-H-0046, 02-
-0111, 03-H-0192, and 04-H-0112). Patients were
tudied to identify the effect of pretransplantation and
ransplantation characteristics on PTRM.
onditioning Regimens
Three conditioning regimens were used in consec-
tive time periods: regimen A consisted of 13.6 Gy of
BI and cyclophosphamide 120 mg/kg, with no lung
hielding, from April 1997 to December 2001 (n  85).
egimen B consisted of 12.0 Gy of TBI with lung
hielding (9.0 Gy to lungs), cyclophosphamide 120 mg/
g, and ﬂudarabine 125 mg/m2 from February 2002 to
ay 2003 (n  35). Regimen C consisted of 12.0 Gy of
BI with lung shielding (6.0 Gy to lungs), cyclophos-
hamide 120 mg/kg, and ﬂudarabine 125 mg/m2 from
une 2003 to August 2004 (n  26). Patients who re-
eived lung shielding had dosage boosts given to the
ediastinum.
ransplantation Approach
In the ﬁrst protocol (97-H-0099), patients re-
eived a T cell–depleted granulocyte colony-stimulat-
ng factor–mobilized PBSCT by using the Ceprate
election system (CellPro, Bothell, WA). Subsequent
rotocols used an Isolex 300 cell separator as previ-
usly described [3]. CD34 cells were positively se-
ected by using anti-CD34 beads, and residual T cells
ere removed with a cocktail of anti-CD2, -CD6, and
CD7 antibody-coated beads. The CD34 cell dose
anged from 2.45 to 15.90  106/kg (median, 5.0 
06/kg); the T-cell dose was 0.2 to 1.0  105 CD3
ells per kilogram recipient weight. In the absence of
VHD or unless molecular remission was docu-
ented in chronic myeloid leukemia (CML), T cells
ere added back on day 45 and 100 (n  140) or day
0 (n  6). The cyclosporine (CSA) dose varied ac-
ording to protocol: 36 received standard-dose CSA
target plasma level, 200-400 ng/mL); 20 received
ow-dose CSA (target plasma level, 100-200 ng/mL),
tarting on day 4 and continuing until an oral dose
as tolerated; and 90 received no CSA during the ﬁrst
weeks after transplantation. All patients started CSA
ither on day 44 (if T cells were added back on day
45) or on day59 (if T cells were added back on day
0), and it was continued until at least day 130 (or
onger, if chronic GVHD occurred). Standard pro-
hylaxis against infection included ﬂuconazole to day p
2400, co-trimoxazole for 6 months after transplanta-
ion, and weekly surveillance for cytomegalovirus an-
igenemia, as described previously [3,4]. Acute
VHD was managed with high-dose steroids. Ste-
oid-refractory patients (no response to 7 days of
reatment) received combined treatment with anti–
umor necrosis factor (inﬂiximab) and anti-CD25 (da-
lizumab) monoclonal antibodies, as described previ-
usly [5].
iagnosis and Management of Posttransplantation
ulmonary Complications
Bronchioalveolar lavage (BAL) was performed on all
atients with undiagnosed pulmonary inﬁltrates. Speci-
ens obtained were submitted for microbiologic cul-
ures and cytopathologic examination. Pulmonary mor-
ality from infectious causes was deﬁned as death from
acterial, viral, or fungal pneumonia or pneumonitis
fter positive culture or by conﬁrmation at autopsy.
cute respiratory distress syndrome (ARDS) was deﬁned
s acute-onset shortness of breath with hypoxia and in-
reased vascular permeability manifested by bilateral
ulmonary inﬁltrates, a ratio of the partial pressure of
rterial oxygen to the fraction of inspired oxygen of
200mmHg regardless of positive end-expiratory pres-
ure, and no evidence of an increased left atrial pressure.
ulmonary hemorrhage was diagnosed during bron-
hoscopy and deﬁned as diffuse alveolar pulmonary in-
ltrates with increasing bloody return on sequential ali-
uots of BAL. Interstitial pneumonitis (IP) was deﬁned
s bilateral pulmonary inﬁltrates with profound hypoxia
fter exclusion of other causes by BAL or by autopsy. IP
nd ARDS were grouped as idiopathic pneumonia syn-
rome (IPS) as deﬁned by an NHLBI workshop [6].
atients who developed pulmonary failure were trans-
erred to intensive care and supported on a ventilator.
ulmonary Function Tests
Baseline pulmonary function tests (PFTs) were
btained in all patients 5 to 21 days before PBSCT.
entilatory capacity was measured by forced vital ca-
acity, forced expiratory volume in the ﬁrst second
FEV1), the FEV1/forced vital capacity ratio, and
eak expiratory ﬂow. Lung volume measurements (by
elium dilution) included vital capacity (VC), total
ung capacity, residual volume, and the residual vol-
me/total lung capacity ratio. Diffusion capacity for
arbon monoxide (DLCO) was determined by using a
arbon monoxide single-breath technique with cor-
ection for hemoglobin concentration. PFTs were ex-
ressed as a percentage of the predicted values in
ealthy controls with corresponding age, sex, and
moking habits. Eligibility criteria for enrollment into
rotocols included DLCO 60% of predicted.
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Pulmonary Transplant-Related Mortality
Bisk Factors for Pulmonary Complications
Patients with CML in ﬁrst chronic phase, acute
eukemia in ﬁrst remission, and myelodysplastic syn-
rome with refractory anemia or refractory anemia with
xcess blasts were categorized as standard risk for trans-
lant-related complications. All other patients were con-
idered at high risk for transplant-related complications.
mokers were deﬁned as patients who regularly smoked
ithin 2 months before PBSCT for a minimum of 2
ears. Busulfan treatment in patients with CML was
eﬁned as more than 30 days of busulfan treatment
efore transplantation.
tatistical Methods
Summary statistics, such as proportions, means,
tandard deviations, 95% conﬁdence intervals, medi-
ns, and ranges, were used to describe the patient
haracteristics, pretransplantation variables, and post-
ransplantation outcomes. Kaplan-Meier estimates and
ox proportional hazard models were used to estimate
he time-to-event distributions of overall survival, re-
apse-free survival, TRM, and PTRM. In particular,
aplan-Meier curves were used to display the distri-
utions of survival and mortality among subgroups of
atients, and Cox proportional hazard models with
nivariate or multivariate covariates were used to eval-
ate the effects of covariates, such as smoking,
LCO, and disease risk, on survival times. Statistical
ssociations between pretransplantation variables
ere investigated by using correlation analysis, includ-
ng Pearson correlation coefﬁcients and Spearman
ank correlation coefﬁcients, and multiple regression
nalysis. Statistical tests based on t tests, 2 tests, and
tests were used to evaluate the statistical signiﬁcance
f covariates in multiple regression models or Cox
roportional hazard models. TheWald score and like-
ihood ratio tests were used to evaluate the ﬁtness of
he Cox proportional hazard models. Data analysis
as performed with Splus (Insightful Corp, Seattle,
A) and SPSS 12 for Windows (SPSS Inc., Chicago,
L) software.
ESULTS
Patient characteristics are summarized in Table 1.
he median follow-up was 1331 days (range, 92-2723
ays), and more than half of the surviving patients were
ollowed up for at least 3 years after transplantation. The
ctuarial overall survival, relapse-free survival, TRM,
nd PTRM of the study group were 58% 4%, 53%
.5%, 16%  3%, and 10.5%  2.5%, respectively
Figure 1). PTRM occurred in 14 patients, accounting
or 67% of all TRM. The characteristics of patients with
TRM are detailed in Table 2. The cause of PTRMwas
nvestigated by BAL or lung biopsy or at autopsy in all
atients. Ten patients died from IPS (IP, n  6; ARDS, a
B&MT 4), and 4 patients died from non-IPS infectious
ulmonary causes. The overall TRM from IPS and non-
PS causes was 6.8% and 2.7%, respectively (Table 3).
he median time to PTRM was 90 days (IPS, 70 days;
on-IPS, 174 days). Ten patients died of IPS between 23
nd 218 days after PBSCT (median, 70 days). Eight of
hese died before day 100 after transplantation.
retransplantation Factors Affecting PTRM
Univariate analysis showed that the pretransplanta-
ion variables smoking, prior busulfan (in CML pa-
ients), DLCO/FEV1/VC (85% of predicted), and
igh-risk disease were associated with increased PTRM
Table 1). Age, sex, race, and diagnosis did not signiﬁ-
antly affect the risk of PTRM. The DLCO, FEV1, and
C were highly correlated (correlation coefﬁcients of
.443, 0.280, and 0.217, respectively, and P values of
.0001, .001, and .008, respectively), but the parameter
ost predictive of outcome was DLCO. Of 47 patients
ith DLCO 85% of predicted and 99 patients with
LCO 85% of predicted, 11 versus 3 had PTRM
P  .0001), and 10 versus 0 had IPS (P  .0001),
espectively. The high-risk group had a higher overall
TRM (9 of 52 versus 5 of 94; P .02) and IPS-related
TRM (7 of 52 versus 3 of 94; P  .02). Actuarial
urvival of the high-risk group was 24.5%  6% com-
ared with 75%  5% in the standard-risk group (P 
0001). Smokers had a higher PTRM (8 of 21 versus 6 of
25; P   .0001), IPS (5 of 21 versus 5 of 125; P 
006), and non-IPS PTRM (3 of 21 versus 1 of 125; P
009). Seven of 56 CML patients had received prior
usulfan. Four of 7 in the busulfan group compared with
of 49 in the no-busulfan group had PTRM (P .001).
imilarly, there was signiﬁcantly higher mortality from
PS in the busulfan group: 3 of 7 versus 1 of 49 (P 
0001). In multivariate analysis, 2 pretransplantation fac-
ors identiﬁed as signiﬁcant in univariate analysis were
ound to be independent variables predictive for PTRM:
LCO 85% and a positive smoking history, with a
elative risk of 5.7 and 5.0, respectively (Table 4). The
LCO and smoking were not correlated (correlation
oefﬁcient, 0.079; P  .344).
ransplant-Related Factors Affecting PTRM
A higher CD34 dose (more than themedian of 5.0
06 CD34 cells per kilogram) was associated with a
igniﬁcant reduction in PTRM (1 of 73 versus 13 of 73;
 .001) and IPS (1 of 73 versus 9 of 73; P .009). CSA
nd T-cell dose did not affect the risk of PTRM (Table 1).
D34 dose was also found to be an independent risk
actor for PTRM in multivariate analysis (patients re-
eiving5 106 CD34 cells per kilogram had a relative
isk of 9.4 for PTRM; Table 4).
In univariate analysis, a higher lung radiation dose
no lung shielding) and a lower CD34 dose were
ssociated with a statistically signiﬁcantly increased
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2isk of PTRM (Table 1). When comparing lung-
hielded (regimens B and C) versus nonshielded (reg-
men A) regimens, a higher PTRM was seen in non–
ung-shielded transplantations (12 of 85 versus 2 of 61;
able 1. Patient Characteristics and Results of Univariate Analysis
Variable
No.
Patients
(%)
Pulmonary
TRM, n
(%)
retransplantation variables
Age, y (range, 10-56;
median, 34)
<34 73 5 (7)
>34 73 9 (12)
Sex
Female 61 (42) 6 (10)
Male 85 (58) 8 (9)
Race
Asian 24 (16) 4 (17)
African American 14 (10) 1 (7)
Hispanic 67 (46) 5 (8)
White 41 (28) 4 (10)
Disease group
CML 56 (38) 6 (11)
AML 38 (26) 5 (13)
MDS 23 (16) 1 (4)
ALL 22 (15) 0 (0)
Other 7 (5) 2 (29)
Conditioning regimens
A 85 (58) 12 (14)
B 35 (24) 2 (6)
C 26 (18) 0 (0)
Disease risk
High 52 (36) 9 (17)
Standard 94 (64) 5 (5)
Smoking
Yes 21 (14) 8 (38)
No 125 (86) 6 (5)
Prior busulfan*
Yes 7 (13) 4 (57)
No 49 (87) 2 (4)
DLCO (% predicted)
(terciles)
<85 47 (32) 11 (23)
85-94 50 (34) 2 (4)
>94 49 (34) 1 (2)
ransplantation variables
Lung shielding (lung dose)
Yes (<1360 cGy) 61 (42) 2 (3)
No (>1360 cGy) 85 (58) 12 (14)
CD34 dose (million cells/kg)
(median)
<5.0 73 13 (18)
>5.0 73 1 (1)
CSA dose
N 90 (61) 9 (10)
LD 20 (14) 1 (5)
SD 36 (25) 4 (11)
T-cell dose
2  104 61 (41) 2 (3)
5  104 49 (34) 8 (16)
1  105 36 (25) 4 (11)
ML indicates chronic myeloid leukemia; AML, acute myeloid leuk
N, no cyclosporine; LD, low dose; SD, standard dose.
CML patients only. .02). There was no difference in PTRM between m
26egimens B and C (lung dose: 900 versus 600 cGy) or
etween regimens A and B versus C (lung dose: 600
ersus 600 cGy), although only 2 of 35 patients in
egimen B (lung dose: 900 cGy) and 0 of 26 in regi-
P
Value
IPS, n
(%)
P
Value
Non-IPS,
n (%)
P
Value
.26 .63 .06
5 (7) 0 (0)
5 (7) 4 (6)
.93 .41 .44
5 (8) 1 (2)
5 (6) 3 (4)
.60 .15 .63
4 (17) 0 (0)
0 (0) 1 (7)
3 (5) 2 (3)
3 (7) 1 (2)
.16 .47 .001
5 (9) 1 (2)
4 (11) 1 (3)
1 (4) 0 (0)
0 (0) 0 (0)
0 (0) 2 (29)
.07 .24 .23
8 (10) 4 (5)
2 (6) 0 (0)
0 (0) 0 (0)
.02 .02 .45
7 (14) 2 (4)
3 (3) 2 (2)
.0001 .006 .009
5 (24) 3 (14)
5 (4) 1 (1)
.001 <.0001 .88
3 (43) 1 (14)
1 (2) 1 (2)
.0001 <.0001 .79
10 (21) 1 (2)
0 (0) 2 (4)
0 (0) 1 (2)
.02 .13 .11
2 (3) 0 (0)
8 (9) 4 (5)
.001 .009 .06
9 (12) 4 (6)
1 (1) 0 (0)
.74 .85 .42
7 (8) 2 (2)
1 (5) 0 (0)
2 (6) 2 (6)
.07 .17 .21
2 (3) 0 (0)
6 (12) 2 (4)
2 (6) 2 (6)
DS, myelodysplastic syndrome; ALL, acute lymphocytic leukemia;<
<
emia; Men C (lung dose: 600 cGy) had PTRM. There was a
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Bigniﬁcant survival advantage with lung shielding (70%
6% versus 52%  5%; P  .04) that was due to less
TRM in this group and a trend to improved relapse-
igure 1. Overall survival (OS) and relapse-free survival (RFS) (A)
nd transplant-related mortality (TRM) and pulmonary TRM
PTRM) (B) for the 146 patients studied.
able 2. Characteristics of Patients with PTRM
Patient
No.
Age
(y) Sex Diagnosis
Disease
Risk Smoking Busulfan*
5 47 F MDS SR N —
7 48 M CML SR Y N
9 47 M MM HR Y —
11 30 F CML HR N Y
37 35 F AML HR N —
39 37 F AML HR N —
42 37 M AML HR Y —
47 21 M CML HR Y Y
51 44 M CLL SR Y —
52 13 F CML HR N Y
55 34 M CML SR Y N
57 44 M AML SR Y —
88 21 M CML HR Y Y
89 41 F AML HR N —
indicates male; F, female; MDS, myelodysplastic syndrome; CML
leukemia; CLL, chronic lymphocytic leukemia; SR, standard r
monoxide; CSA, cyclosporine; SD, standard dose; N, no cyclosp
RSV, respiratory syncytial virus; ARDS, acute respiratory distreCML patients only.
B&MTree survival (60%  7% versus 36%  8%; P  .07)
n lung-shielded patients. However, lung shielding did
ot emerge as an independent predictive factor for
TRM in multivariate analysis.
ISCUSSION
Historically, pulmonary complications have been a
ajor cause of morbidity after allogeneic SCT. They
ccur in 40% to 50% of patients and have a mortality of
0% to 50% [7-13]. The spectrum of pulmonary com-
lications includes infectious and noninfectious etiolo-
ies. Common early complications include pulmonary
dema, infectious pneumonia, IP, ARDS, and diffuse
lveolar hemorrhage. Noninfectious pulmonary compli-
ations are a particular concern because they respond
oorly to standard therapeutic approaches and contrib-
te substantially to TRM. AnNHLBI workshop deﬁned
idespread alveolar injury after SCT that occurs in the
bsence of an active lower respiratory tract infection and
O
)
Lung
Dose
(cGy)
CD34
Dose
(104/kg)
CSA
Dose
T-Cell
Dose/kg
Survival
(d)
Pulmonary
TRM
1360 4.63 SD 1  105 71 IP
1360 4.84 SD 1  105 238 CMV
1360 3.72 SD 1  105 172 RSV
1360 4.42 SD 1  105 90 IP
1360 4.27 N 5  104 46 IP
1360 3.70 N 5  104 187 CMV
1360 4.74 N 5  104 23 ARDS
1360 3.68 N 5  104 108 IP
1360 3.80 N 5  104 103 Bacterial
1360 4.51 LD 5  104 69 IP
1360 12.80 N 5  104 44 ARDS
1360 3.09 N 5  104 216 ARDS
900 4.86 N 2  104 89 ARDS
900 2.72 N 2  104 60 IP
ic myeloid leukemia; MM, multiple myeloma; AML, acute myeloid
, high risk; Y, yes; N, no; DLCO, diffusion capacity for carbon
D, low dose; IP, interstitial pneumonitis; CMV, cytomegalovirus;
rome.
able 3. Causes of PTRM
PTRM n %
PS 10 6.8
IP 6 4.1
ARDS 4 2.7
on-IPS 4 2.7
CMV 2 1.4
RSV 1 0.7
Bacterial 1 0.7
otal PTRM 14/146 9.6
TRM indicates pulmonary transplant-related mortality; IPS, ideo-
pathic pneumonia syndrome; IP, interstitial pneumonitis;
ARDS, acute respiratory distress syndrome; CMV, cytomegalo-
virus; RSV, respiratory syncytial virus.DLC
(%
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2ardiogenic causes as IPS [6]. In this study, we have
herefore included IP and ARDS in the category of IPS
s deﬁned by theNHLBI workshop. The actuarial prob-
bility of PTRM in our study was 10.4%  2.7%, with
.4% death due to IPS, and this is within the range
eported in the literature [14-16]. In a meta-analysis of
2 studies of 4496 patients summarized by Afessa et al.,
17] the overall incidence of IPS was 10% (range, 2%-
7%). It varied with the patient population studied, with
ifferences in the diagnostic methods used, and by the
ack of a uniform deﬁnition of IPS. The mortality rate
stimate was 74% (range, 60%-90%) regardless of ther-
py. In this analysis, the proportion of patients who died
f IPS was high (67% of all PTRM) compared with
revious reports [18]. The higher proportion of nonin-
ectious causes of PTRMmay reﬂect improved outcome
or infectious pulmonary complications: in our study,
nly 2.7% patients died from infectious pulmonary com-
lications.
Earlier studies have sought to deﬁne risk factors
or severe pulmonary complications that lead to
TRM, included conditioning with TBI (lung shield-
ng versus no shielding), GVHD, older recipient age,
se of methotrexate for GVHD prophylaxis, pre-SCT
mpaired pulmonary function as measured by PFTs,
ore advanced disease status, HLA disparity, longer
uration from diagnosis to SCT, and decreased pre-
CT performance status [7,10,11,13,19-26]. Some of
hese factors were shown to be independent variables
n multivariate analysis.
Several studies have described an association of IPS
nd GVHD [10,11,13,17-19,24,27] and have suggested
hat GVHD may synergize with regimen-induced lung
amage to cause IPS. Murine models show that alloreac-
ive T cells and radiation conditioning induce GVHD
nd IPS under conditions in which neither could do so
ndividually [28,29]. Clinical evidence also suggests that
oth non–immune-mediated and immune-mediated
ung injury contribute to the development of IPS, be-
ause despite a comparable incidence of GVHD, IPS
requency was lower after nonmyeloablative condition-
ng than after a conventional myeloablative regimen
22]. In our study, none of the 14 patients who died of
able 4. Multivariate Cox Regression Analysis of Risk Factors for PTR
Factor
Estimate of
Coefficient () R
LCO (% predicted)
>85
<85 1.74
moking
No
Yes 1.61
D34 dose
>5.0 million cells/kg
<5.0 million cells/kg 2.24TRM had signiﬁcant GVHD. .
28There is a general perception that over the last de-
ade, TRM and associated PTRM have diminished in
art because of more effective management of infectious
omplications (especially cytomegalovirus [30]), re-
uced-intensity conditioning regimens, [13,17,22] and
ung shielding during TBI [31-34]. This analysis evalu-
ted risk factors for PTRM in the context of these im-
rovements. We found that pretransplantation smoking
istory, busulfan exposure in CML patients, and, most
otably, PFTs can predict which patients are at risk from
TRM.Of these factors, smoking and decreasedDLCO
85% of predicted) were found to be independent risk
actors that increased the risk of PTRM 5.0- and 5.7-
old, respectively. Our study showed a strong correlation
etween DLCO, FEV1, and VC and PTRM. We se-
ected DLCO as the most useful predictive parameter
ecause reduced diffusion capacity most closely reﬂects
he main pathology (reduced oxygenation from reduced
iffusion) in mechanically ventilated patients dying from
ulmonary failure. Our results concord with previous
eports that demonstrated an association between pre-
ransplantation PFT and early mortality after SCT
15,24,35,36]. Crawford and Fisher [35] studied the pre-
ictive value of pretransplantation PFTs and pulmonary
orbidity after SCT. They found that DLCO80% of
redicted was signiﬁcantly associated with mechanical
entilation and death after transplantation. However,
halie et al. [16] found no association between abnormal
retransplantation PFT and fatal pulmonary complica-
ions. It cannot be excluded from our data that pretrans-
lantation PFTs were a surrogate for other mechanisms
f tissue damage that affect mortality (eg, diminished
iffusion capacity as a marker of diffuse endothelial in-
ury or potential for hepatic veno-occlusive disease [37]).
It is interesting to note that pretransplantation
moking was associated with signiﬁcantly increased
TRM in our analysis (38% versus 4.8%; P  .0001).
his contrasts with a study by Ho et al., [36] who
ound that tobacco use was not associated with in-
reased severe pulmonary complications after alloge-
eic SCT. Busulfan was associated with a signiﬁcantly
ncreased risk of PTRM (4 of 7 versus 2 of 49; P 
e
)
95% Confidence Interval
for Relative Risk
P Value for
  0
1.95-16.75 .001
1.57-15.97 .001
1.15-76.26 .03M
Relativ
isk (e
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5.7
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Borrelated, thus indicating that busulfan was an inde-
endent risk factor for PTRM in CML.
High-risk disease was associated with increased
TRM in univariate analysis only in our study.
ther investigators found no association between
isease risk and IPS [22] or early pulmonary com-
lications [36].
An assessment of DLCO and smoking history
ay identify patients at risk from PTRM who might
eneﬁt most from reduced lung irradiation, higher
D34 transplant doses, and efﬁcient GVHD pro-
hylaxis to reduce the risk of pulmonary damage
fter SCT. The effect of these factors on PTRM
equires further validation in prospective studies.
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